Update Series (2026): Perioperative Management of Urinary Diversion

Update Series (2026): Perioperative Management of Urinary Diversion: What Every Urologist Should Know Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Rohit Reddy, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

Update Series (2026): Perioperative Management of Urinary Diversion: What Every Urologist Should Know Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Rohit Reddy, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AUA2026: Advanced Cystoscopy Training for APPs Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Brett Johnson, MD and Davis Viprakasit, MD, FACS Tune in to hear straight from the experts about our newest Hands-On Skills Training offering - Advanced Cystoscopy Training for APPs, part of the pre-meeting programming at AUA2026! In this episode, Dr. Brett Johnson and Dr. Davis Viprakasit discuss all about what you can expect from the Advanced Cystoscopy Training for APPs, a new APP hands-on skills training being held at AUA2026. This training provides both a half-day of hands-on skills training in the most critical procedural areas of need for APPs, as well as a library of on-demand virtual didactics straight from the experts. Spaces are still available - for more information or to register, please visit https://www.auanet.org/AUA2026/program/pre-meeting-programs Outline: Segment #1: Why offer the Advanced Cystoscopy Training for APPs? Segment #2: Description of the course Segment #3: Unique aspects of the course Segment #4: Potential benefits to participants Segment #5: Future directions

LG-IR-NMIBC Treatment Landscape (Republished) Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Chad R. Ritch, MD, MBA, FACS CME Available: cme.auanet.org/URL/GUPOD251 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Differentiate between traditional and emerging intravesical therapies for LG-IR-NMIBC, considering mechanism of action, administration schedules, and patient eligibility to support individualized treatment planning. 2. Incorporate into practice shared decision-making strategies that align clinical recommendations with patient values, preferences, and quality-of-life considerations in the management of LG-IR-NMIBC. 3. Utilize practical approaches for integrating intravesical therapy into routine clinical workflows, including coordination among multidisciplinary teams, patient education, and follow-up to optimize adherence and outcomes.

NMIBC Treatment Landscape (Republished) Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Janet Kukreja, MD, MPH, FACS CME Available: https://cme.auanet.org/URL/GUPOD253 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs. 2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence. 3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.

MIBC Treatment Landscape (Republished) Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Jen-Jane Liu, MD, FACS CME Available: https://cme.auanet.org/URL/GUPOD252 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors. 2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning. 3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.

AUA2025: Key Takeaways: Bladder Cancer Presenters: Patrick Hensley, MD & Janet Kukreja, MD

Update Series (2026) Lesson 5: Long-term Urinary Catheters: Their Role & Management of Complications Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit https://cme.auanet.org/URL/US2026

Adjuvant Therapy for Renal Cell Carcinoma Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Daniel Shapiro, MD, FACS CME Available: https://cme.auanet.org/URL/RCCPOD261 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from: Merck & Co., Inc. LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Define adjuvant therapy, review current clinical guidelines, and recognize the current landscape of treatment options for patients with RCC. 2. Compare and contrast different adjuvant therapies available for RCC, including targeted therapies and immunotherapies. 3. Identify common side effects associated with adjuvant therapies for RCC and provide strategies for managing and mitigating these adverse events in clinical practice. 4. Discuss ongoing clinical trials and new therapeutic targets under investigation for adjuvant treatment of RCC.

Use of Suction Ureteroscopes for Kidney Stone Treatment: CVAC System Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Karen L. Stern, MD